– Neuralstem Releases Full Data Set for NSI-189 MDD Trial Showing Patient Rated Outcome and Cognitive Benefits
– Nature Medicine Paper Demonstrates Benefit of NSI-566 on Paralysis in Non-Human Primates
GERMANTOWN, Md., April 02, 2018 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, reported its financial results for the year ended December 31, 2017.
We remain committed to the development of NSI-566, our lead stem cell therapy candidate, and NSI-189 for major depressive disorder (MDD), which we believe offer novel modalities of treatments for patients that are not effectively treated by current therapies, sa…
Read the full article at: https://globenewswire.com/news-release/2018/04/02/1458379/0/en/Neuralstem-Reports-Year-End-2017-Fiscal-Results-and-Business-Update.html